The Houssay Phenomenon in Man: Recovery from Retinopathy in a Case of Diabetes With Simmonds' Disease

No abstract is available for this paper.

• Publication year

  1953

• Venue

  Diabetes

• Publication date

  1953-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2337/diab.2.1.7PMID 13020938
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pituitary Necrosis in a Diabetic During Pregnancy: The Houssay Phenomenon In Man

  1952cited by this paper
• Diabetic retinopathy.

  1952cited by this paper
• Unrecognized pituitary necrosis (Sheenhan's syndrome), a cause of sudden death.

  1952cited by this paper
• Pituitary necrosis and diabetes mellitus.

  1951cited by this paper
• Coincidence of diabetes mellitus and hypopituitarism.

  1947cited by this paper
• Simmonds's Disease Due to Postpartum Necrosis of the Anterior Pituitary

  1943cited by this paper
• Studies on ketosis in diabetes mellitus.

  1941cited by this paper
• THE HOUSSAY PHENOMENON IN MAN: REPORT OF A CASE OF DIABETES MELLITUS, INFARCT OF THE ANTERIOR LOBE OF THE PITUITARY BODY AND TERMINAL HYPOGLYCEMIA

  1940cited by this paper
• Diabetes mellitus and the pituitary gland.

  1935cited by this paper

• The Role and Diagnostic Potential of Insulin-like Growth Factor 1 in Diabetic Retinopathy and Diabetic Macular Edema

  2025cites this paper
• Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management

  2024cites this paper
• Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited

  2022cites this paper
• Regression of Diabetic Macular Edema by Remission of Type 2 Diabetes with Plant-Based Diet: A Case Report and Review

  2022cites this paper
• The role of growth hormone and IGF-1 in retinopathy: a prospective study of retinopathy in patients with acromegaly and impaired fasting glucose

  2021cites this paper
• Lipid Metabolism in Urban Residents with Type 2 Diabetes and Cardiovascular Diseases

  2021cites this paper
• Nonproliferative and Proliferative Diabetic Retinopathy

  2021cites this paper
• Current Approaches in Treatment of Diabetic Retinopathy and Future Perspectives

  2020cites this paper
• Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy

  2020cites this paper
• Increased Number of Retinal Vessels in Acromegaly.

  2020cites this paper
• DIABETES MELLITUS AND DEFECTIVE PITUITARY RESERVE CAPACITY

  2020cites this paper
• Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?

  2019cites this paper
• Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

  2018cites this paper
• Somatostatin and diabetic retinopathy: an evolving story

  2018cites this paper
• Somatolactogens and diabetic retinopathy.

  2018cites this paper
• Diabetic Retinopathy: Lakatosian Analysis from the Perspective of Medical Bioengineering

  2018cites this paper
• Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy

  2017cites this paper
• Diagnosis and treatment of diabetic retinopathy — historical overview

  2017cites this paper
• Reflections on "Hot" Blind Spots: Lessons from Research on Aging Macula Disorder and Glaucoma

  2017cites this paper
• From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis

  2017cites this paper
• Abnormal vascular and neural retinal morphology in congenital lifetime isolated growth hormone deficiency.

  2016cites this paper
• IGF-1 in retinopathy of prematurity, a CNS neurovascular disease.

  2016cites this paper
• Growth hormone and ocular dysfunction: Endocrine, paracrine or autocrine etiologies?

  2016cites this paper
• IGF-I in the clinics: Use in retinopathy of prematurity.

  2016cites this paper
• Current nanotechnology approaches for the treatment and management of diabetic retinopathy.

  2015cites this paper
• Multifactorial processes to slowing the biological clock: Insights from a comparative approach.

  2015cites this paper
• Prolactine placentaire et anomalies de croissance au cours du diabète maternel

  2014cites this paper
• Incidence of retinopathy changes in new cases of diabetesmellitus type 2

  2013cites this paper
• Chapter 48 – Proliferative Diabetic Retinopathy

  2013cites this paper
• Insulin analogues may accelerate progression of diabetic retinopathy after impairment of inner blood-retinal barrier.

  2013cites this paper
• Mouse models of diabetic retinopathy

  2013cites this paper
• Chapter 26 – Basic Mechanisms of Pathological Retinal and Choroidal Angiogenesis

  2013cites this paper
• A stem cell based approach for vascular repair in diabetic retinopathy

  2012cites this paper
• Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

  2012cites this paper
• Medical Management of Diabetic Retinopathy

  2011cites this paper
• Reflections on "hot" blind spots: lessons from research on aging macula disorder and glaucoma: the Weisenfeld lecture.

  2011cites this paper
• mellitus (clinical conference) Hypertension, the endothelial cell, and the vascular complications of diabetes

  2011cites this paper
• Serum insulin-like growth factor-I in diabetic retinopathy

  2011cites this paper
• Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy

  2011cites this paper
• Stimulating effect of growth hormone on type IV collagen production by endothelial cells cultured in normal and high glucose

  2011cites this paper
• A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer.

  2011cites this paper
• Gestational Diabetes Mellitus and Obesity

  2010cites this paper
• Endocrine Disorders that Cause Diabetes

  2010cites this paper
• Adrenals and Serum Polysaccharides

  2009cites this paper
• Administration of DDD (2, 2-bis(parachlorophenyl)-1, 1-dichloroethane) to diabetics with hyaline vascular changes and hyperpolysaccharidemia; a preliminary report.

  2009cites this paper
• Long-term insulin-dependent diabetes mellitus with secondary pituitary insufficiency and regression of retinopathy.

  2009cites this paper
• Renal lesions due to fluctuations in blood sugar levels.

  2009cites this paper
• Body Composition and Adipokine Levels in Growth Hormone Antagonist Mice

  2009cites this paper
• The role of liver-derived insulin-like growth factor-I.

  2009cites this paper
• Sheehan's syndrome of hypothalamic origin in a woman with juvenile diabetes mellitus.

  2009cites this paper
• Treating diabetic retinopathy by inhibiting growth factor pathways.

  2009cites this paper
• Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.

  2008cites this paper
• Antagonism of the Growth Hormone Axis as a Therapeutic Strategy for Diabetic Retinopathy

  2008cites this paper
• Cuantificación de eritropoyetina y somatostatina intravítrea: estudio comparativo entre pacientes con diabetes mellitus y trombosis venosa retiniana

  2008cites this paper
• PHARMACOTHERAPY FOR DIABETIC RETINOPATHY - IT IS NOT JUST A DREAM

  2008cites this paper
• Beyond VEGF – Other Factors Important in Retinal Neovascularization: Potential Targets in Proliferative Diabetic Retinopathy

  2008cites this paper
• Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture.

  2008cites this paper
• [Growth hormone and delayed diabetic complications].

  2008cites this paper
• Novel Therapeutic Strategies For Posterior Segment Neovascularization

  2008cites this paper
• Diabetic retinopathy and blindness in Spain: epidemiology and prevention.

  2008cites this paper
• Pharmacotherapy for diabetic retinopathy - it is not just a dream.

  2008cites this paper
• "Diabetic retinopathy; from glycation to clinical aspects"

  2008cites this paper
• Use of long-acting somatostatin analogue treatment in diabetic retinopathy.

  2007cites this paper
• Retinopathy of prematurity

  2007cites this paper
• Pathogenesis and Classification of Proliferative Diabetic Vitreoretinopathy

  2007cites this paper
• Retinal and choroidal microangiopathies: therapeutic opportunities.

  2007cites this paper
• Medical treatment of diabetic retinopathy with somatostatin analogues

  2007cites this paper
• Discovery and uses of pegvisomant: a growth hormone antagonist.

  2007cites this paper
• Pharmacotherapy of Diabetic Retinopathy

  2007cites this paper
• Diabetic retinopathy: pathogenesis, prevention, and treatment

  2007cites this paper
• IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development

  2007cites this paper
• Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice

  2007cites this paper
• Diabetic retinopathy in acromegaly

  2006cites this paper
• Parakrine Faktoren bei der diabetischen Retinopathie

  2006cites this paper
• Growth hormone hypothesis and development of diabetic nephropathy in Type 1 diabetes

  2006cites this paper
• Insulin-like Growth Factor-I and Its Binding Proteins: Regulation of Secretion and Mechanism of Action at the Receptor Level

  2006cites this paper
• Deterioration of Visual Acuity Associated with Growth Hormone Therapy in a Child with Extreme Short Stature and High Hypermetropia

  2006cites this paper
• Chapter 68 – Proliferative Diabetic Retinopathy

  2006cites this paper
• Retinopathy of Prematurity: Molecular Mechanism of Disease

  2006cites this paper
• Diabetic retinopathy: an historical assessment.

  2006cites this paper
• Traitement médical de la rétinopathie diabétique

  2006cites this paper
• Anti-VEGF Therapies for Diseases of the Retina and Choroid

  2006cites this paper
• Chapter 141 – Intraocular Neovascularization

  2006cites this paper
• Growth Hormone Antagonists: A Pharmacological Tool in Present and Future Therapies

  2006cites this paper
• Potential future targets for treating ocular neovascularization.

  2006cites this paper
• Chapter 66 – Etiologic Mechanisms in Diabetic Retinopathy

  2005cites this paper
• Novel approaches in the treatment of angiogenic eye disease.

  2005cites this paper
• The Potential Role of Octreotide in the Treatment of Diabetic Retinopathy

  2005cites this paper
• Pegvisomant: Current and possible future indications

  2005cites this paper
• Current and future pharmacological intervention for diabetic retinopathy

  2005cites this paper
• Insulin-Like Growth Factor-1 and Its Binding Proteins, IGFBP-1 and IGFBP-3, in Adolescents with Type-1 Diabetes mellitus and Microalbuminuria

  2005cites this paper
• Pathogenesis of retinopathy of prematurity.

  2004cites this paper
• The role of growth factors in the pathogenesis of diabetic retinopathy

  2004cites this paper
• Clinical review 166: Growth hormone receptor antagonists.

  2004cites this paper
• Therapie der diabetischen Retinopathie mit Somatostatinanaloga

  2004cites this paper
• Current approaches and perspectives in the medical treatment of diabetic retinopathy.

  2004cites this paper
• INVESTIGATION OF RELATION BETWEEN BASAL AND STIMULATED LEVELS OF GROWTH HORMONE AND PROTEINURIA IN TYPE 2 DIABETIC PATIENTS

  2004cites this paper
• The role of the biochemistry department in the diagnosis of pituitary apoplexy

  2004cites this paper
• Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.

  2004cites this paper
• Pharmacotherapy for diabetic retinopathy

  2004cites this paper